JP2014525926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525926A5 JP2014525926A5 JP2014525434A JP2014525434A JP2014525926A5 JP 2014525926 A5 JP2014525926 A5 JP 2014525926A5 JP 2014525434 A JP2014525434 A JP 2014525434A JP 2014525434 A JP2014525434 A JP 2014525434A JP 2014525926 A5 JP2014525926 A5 JP 2014525926A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- region
- combination
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *CCN(CCCl)c1ccc(CCCC(O)=O)cc1 Chemical compound *CCN(CCCl)c1ccc(CCCC(O)=O)cc1 0.000 description 2
- WAMNGGHTLRINPS-UHFFFAOYSA-N CCCN(CCCO1)P1(NCCCl)=O Chemical compound CCCN(CCCO1)P1(NCCCl)=O WAMNGGHTLRINPS-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N N[C@@H](Cc(cc1)ccc1N(CCCl)CCCl)C(O)=O Chemical compound N[C@@H](Cc(cc1)ccc1N(CCCl)CCCl)C(O)=O SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N O=C(C(N(CCCl)CCCl)=CN1)NC1=O Chemical compound O=C(C(N(CCCl)CCCl)=CN1)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N O=P1(N(CCCl)CCCl)OCCCN1 Chemical compound O=P1(N(CCCl)CCCl)OCCCN1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
Images
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523861P | 2011-08-16 | 2011-08-16 | |
| US61/523,861 | 2011-08-16 | ||
| EP11177658 | 2011-08-16 | ||
| EP11177658.9 | 2011-08-16 | ||
| US201261647539P | 2012-05-16 | 2012-05-16 | |
| US61/647,539 | 2012-05-16 | ||
| US201261654097P | 2012-06-01 | 2012-06-01 | |
| US61/654,097 | 2012-06-01 | ||
| PCT/EP2012/065906 WO2013024097A1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014525926A JP2014525926A (ja) | 2014-10-02 |
| JP2014525926A5 true JP2014525926A5 (https=) | 2015-10-01 |
| JP6184952B2 JP6184952B2 (ja) | 2017-08-23 |
Family
ID=47714801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014525434A Active JP6184952B2 (ja) | 2011-08-16 | 2012-08-14 | 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20140255427A1 (https=) |
| EP (2) | EP2744515B1 (https=) |
| JP (1) | JP6184952B2 (https=) |
| KR (3) | KR20140064873A (https=) |
| CN (1) | CN103732252B (https=) |
| AU (1) | AU2012296907B2 (https=) |
| BR (1) | BR112013033919B1 (https=) |
| CA (2) | CA2841875C (https=) |
| CY (1) | CY1125122T1 (https=) |
| DK (1) | DK2744515T3 (https=) |
| ES (1) | ES2909722T3 (https=) |
| HR (1) | HRP20220228T1 (https=) |
| HU (1) | HUE058350T2 (https=) |
| IL (1) | IL230293B (https=) |
| LT (1) | LT2744515T (https=) |
| MX (1) | MX354479B (https=) |
| PL (1) | PL2744515T3 (https=) |
| PT (1) | PT2744515T (https=) |
| RS (1) | RS63238B1 (https=) |
| RU (1) | RU2625222C2 (https=) |
| SG (1) | SG10201606785UA (https=) |
| SI (1) | SI2744515T1 (https=) |
| SM (1) | SMT202200159T1 (https=) |
| WO (1) | WO2013024097A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015277516A1 (en) * | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| LT3302550T (lt) * | 2015-05-26 | 2019-11-11 | Morphosys Ag | Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas |
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| FI3916392T3 (fi) * | 2016-05-30 | 2024-06-03 | Incyte Corp | Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla |
| US12358983B2 (en) * | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| EP3548055A4 (en) | 2016-12-02 | 2020-08-19 | University of Southern California | SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE |
| LT3630177T (lt) * | 2017-05-31 | 2023-10-25 | Morphosys Ag | Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CA3255552A1 (en) * | 2021-12-22 | 2023-06-29 | Incyte Corporation | TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| US7112324B1 (en) * | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| WO2000067796A1 (en) * | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| JP2004508420A (ja) | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法 |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| MX2007005361A (es) | 2004-11-05 | 2008-01-11 | Cephalon Inc | Tratamientos para cancer. |
| CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
| PL2383297T3 (pl) * | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| RU2495882C2 (ru) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| EA201170940A1 (ru) * | 2009-01-16 | 2012-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| AU2010263272C1 (en) | 2009-06-24 | 2016-02-11 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| CA2769595A1 (en) * | 2009-08-14 | 2011-02-17 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone |
| US20110135739A1 (en) * | 2009-11-06 | 2011-06-09 | Bennett Carter | Oral Formulations of a Hedgehog Pathway Inhibitor |
-
2012
- 2012-08-14 KR KR1020147006936A patent/KR20140064873A/ko not_active Ceased
- 2012-08-14 SI SI201231989T patent/SI2744515T1/sl unknown
- 2012-08-14 DK DK12747923.6T patent/DK2744515T3/da active
- 2012-08-14 CA CA2841875A patent/CA2841875C/en active Active
- 2012-08-14 SM SM20220159T patent/SMT202200159T1/it unknown
- 2012-08-14 PL PL12747923T patent/PL2744515T3/pl unknown
- 2012-08-14 CN CN201280036571.XA patent/CN103732252B/zh active Active
- 2012-08-14 KR KR1020197026462A patent/KR102115203B1/ko active Active
- 2012-08-14 EP EP12747923.6A patent/EP2744515B1/en active Active
- 2012-08-14 BR BR112013033919-5A patent/BR112013033919B1/pt active IP Right Grant
- 2012-08-14 RS RS20220412A patent/RS63238B1/sr unknown
- 2012-08-14 JP JP2014525434A patent/JP6184952B2/ja active Active
- 2012-08-14 WO PCT/EP2012/065906 patent/WO2013024097A1/en not_active Ceased
- 2012-08-14 EP EP22155572.5A patent/EP4062936A1/en active Pending
- 2012-08-14 HU HUE12747923A patent/HUE058350T2/hu unknown
- 2012-08-14 MX MX2013014933A patent/MX354479B/es active IP Right Grant
- 2012-08-14 CA CA3137321A patent/CA3137321A1/en active Pending
- 2012-08-14 HR HRP20220228TT patent/HRP20220228T1/hr unknown
- 2012-08-14 SG SG10201606785UA patent/SG10201606785UA/en unknown
- 2012-08-14 AU AU2012296907A patent/AU2012296907B2/en active Active
- 2012-08-14 US US14/126,928 patent/US20140255427A1/en not_active Abandoned
- 2012-08-14 KR KR1020207014299A patent/KR20200058583A/ko not_active Withdrawn
- 2012-08-14 PT PT127479236T patent/PT2744515T/pt unknown
- 2012-08-14 LT LTEPPCT/EP2012/065906T patent/LT2744515T/lt unknown
- 2012-08-14 ES ES12747923T patent/ES2909722T3/es active Active
- 2012-08-14 RU RU2014103492A patent/RU2625222C2/ru active
-
2014
- 2014-01-02 IL IL230293A patent/IL230293B/en active IP Right Grant
-
2020
- 2020-04-03 US US16/839,777 patent/US20200353077A1/en not_active Abandoned
-
2022
- 2022-04-18 CY CY20221100289T patent/CY1125122T1/el unknown
-
2024
- 2024-01-12 US US18/411,350 patent/US20240366756A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022202796B2 (en) | Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof | |
| US20240366756A1 (en) | Combinations and uses thereof | |
| JP6114273B2 (ja) | 抗−ｃｄ１９抗体とプリン類似体の併用治療 | |
| JP2014525926A5 (https=) | ||
| JP2014525925A5 (https=) | ||
| JP2025131697A (ja) | 組み合わせおよびその使用 | |
| AU2012296907A1 (en) | Combination therapy with an anti - CD19 antibody and a nitrogen mustard | |
| HK40081594A (en) | Combination therapy with an anti-cd19 antibody and a nitrogen mustard | |
| NZ617770B2 (en) | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |